These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 8492922)

  • 1. Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study.
    Kurth MC; Tetrud JW; Irwin I; Lyness WH; Langston JW
    Neurology; 1993 May; 43(5):1036-9. PubMed ID: 8492922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
    Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.
    Metman LV; Hoff J; Mouradian MM; Chase TN
    Mov Disord; 1994 Jul; 9(4):463-5. PubMed ID: 7969216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.
    Othman AA; Chatamra K; Mohamed ME; Dutta S; Benesh J; Yanagawa M; Nagai M
    Clin Pharmacokinet; 2015 Sep; 54(9):975-84. PubMed ID: 25875940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid levodopa-carbidopa in advanced Parkinson's disease with motor complications.
    Yang HJ; Ehm G; Kim YE; Yun JY; Lee WW; Kim A; Kim HJ; Jeon B
    J Neurol Sci; 2017 Jun; 377():6-11. PubMed ID: 28477709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levodopa/carbidopa microtablets in Parkinson's disease: a study of pharmacokinetics and blinded motor assessment.
    Senek M; Aquilonius SM; Askmark H; Bergquist F; Constantinescu R; Ericsson A; Lycke S; Medvedev A; Memedi M; Ohlsson F; Spira J; Westin J; Nyholm D
    Eur J Clin Pharmacol; 2017 May; 73(5):563-571. PubMed ID: 28101657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.
    Müller T; Ander L; Kolf K; Woitalla D; Muhlack S
    J Neural Transm (Vienna); 2007; 114(11):1457-62. PubMed ID: 17564755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
    Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT
    Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and efficacy of a novel formulation of carbidopa-levodopa (Accordion Pill
    LeWitt PA; Giladi N; Navon N
    Parkinsonism Relat Disord; 2019 Aug; 65():131-138. PubMed ID: 31176632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Breck L; Kutt H; McDowell FH
    Neurology; 1987 Feb; 37(2):233-41. PubMed ID: 3808304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.
    Stocchi F; Hsu A; Khanna S; Ellenbogen A; Mahler A; Liang G; Dillmann U; Rubens R; Kell S; Gupta S
    Parkinsonism Relat Disord; 2014 Dec; 20(12):1335-40. PubMed ID: 25306200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations.
    Kurth MC; Tetrud JW; Tanner CM; Irwin I; Stebbins GT; Goetz CG; Langston JW
    Neurology; 1993 Sep; 43(9):1698-703. PubMed ID: 8414015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease.
    Delea TE; Thomas SK; Hagiwara M; Mancione L
    Curr Med Res Opin; 2010 Jul; 26(7):1543-52. PubMed ID: 20429819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation.
    Pappert EJ; Goetz CG; Niederman F; Ling ZD; Stebbins GT; Carvey PM
    Neurology; 1996 Dec; 47(6):1493-5. PubMed ID: 8960733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of IPX066 , an extended release carbidopa-levodopa formulation, for the treatment of Parkinson's disease.
    Kestenbaum M; Fahn S
    Expert Opin Drug Saf; 2015 May; 14(5):761-7. PubMed ID: 25697185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease.
    Chen C; Cowles VE; Sweeney M; Stolyarov ID; Illarioshkin SN
    J Clin Pharmacol; 2012 Jul; 52(7):1069-77. PubMed ID: 21610205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IPX066: a novel carbidopa-levodopa extended-release formulation.
    Hauser RA
    Expert Rev Neurother; 2012 Feb; 12(2):133-40. PubMed ID: 22288668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-acting carbidopa-levodopa in the management of moderate and advanced Parkinson's disease.
    Hutton JT; Morris JL
    Neurology; 1992 Jan; 42(1 Suppl 1):51-6; discussion 57-60. PubMed ID: 1549202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of controlled-release carbidopa/levodopa on motor performance in advanced Parkinson's disease.
    Rondot P; Ziegler M; Aymard N; Teinturier A
    Neurology; 1989 Nov; 39(11 Suppl 2):74-7; discussion 95. PubMed ID: 2586765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
    Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.